One Boston Scientific Place Natick MA 01760-1537 USA [t] 001 888-272-1001
Boston Scientific is the world’s largest medical device company dedicated to developing less-invasive medical devices and procedures.
The company delivers more than 15,000 products in over 45 countries and operates 26 manufacturing, distribution and technology centres.
Every year Boston Scientific enrolls tens of thousands of patients in pre- and post-approval clinical studies and the company regularly submits news reports on the outcomes of these studies.
Boston Scientific reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.
Boston Scientific completes a first-in-human clinical trial utilising the IntellaTip MiFi XP Ablation Catheter for the treatment of type 1 atrial flutter, an arrhythmia originating in the right atrium of the heart that affects nearly one million people in the USA.
The first patient in the USA is implanted with the Boston Scientific next generation ImageReady MR Conditional pacing system in the SAMURAI clinical trial.
Boston Scientific receives approval by the US Food and Drug Administration and is beginning a limited launch of the Precision Spectra Spinal Cord Stimulator (SCS) System.
Boston Scientific receives CE Mark approval for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch.
The first patient has been treated in the Boston Scientific ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer Open-Irrigated Temperature Ablation Catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation.
The first patient is implanted with the Boston Scientific's next generation INGEVITY pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads.
The first patient enrolls in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the SYNERGY Stent System and support US Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
Boston Scientific receives CE Mark approval for increased longevity projections for the INCEPTA, ENERGEN, PUNCTUA, COGNIS and TELIGEN implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).
Boston Scientific and the University of Rochester Medical Center are presenting positive results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) clinical trial that demonstrated improved programming of the Boston Scientific dual-chamber implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) heart devices can reduce inappropriate therapy and risk of death.
Boston Scientific is reporting clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element Everolimus-Eluting Platinum Chromium (PtCr) Stent System in patients with long coronary lesions.
The US Food and Drug Administration grants Boston Scientific regulatory approval for the company's S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).
The US Food and Drug Administration has granted Boston Scientific regulatory approval for the company's S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).
Boston Scientific receives US Food and Drug Administration clearance for the Emerge Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States.
Boston Scientific receives CE Mark approval for use of the company's Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease.
Boston Scientific is launching in European countries the PROMUS ELEMENT PLUS BTK (Below The Knee) Everolimus-Eluting Stent System for the treatment of certain severe peripheral artery lesions.
Boston Scientific receives CE Mark approval for use of the company's PRECISION PLUS SPINAL CORD STIMULATOR (SCS) System in patients with the system and are in need for magnetic resonance imaging (MRI) head-only scans.
Boston Scientific receives CE Mark approval for use of its INGENIO and ADVANTIO pacemakers in patients in need of a magnetic resonance imaging (MRI) scan.
Boston Scientific completes enrollment in the PREVAIL confirmatory study, designed to gain US Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage (LAA) Closure device.
The US Food and Drug Administration (FDA) is providing Boston Scientific regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation drug-eluting stent (DES) technology.
Boston Scientific receives the CE Mark for the company's the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Boston Scientific is collaborating with Philips in a deal which will see Philips sell Boston Scientific Imaging equipment in connection with its Allura Xper catheterization (cath) lab systems in territories throughout the world.
Boston Scientific is introducing extended warranties of up to 10 years, depending on the model, for its ENERGEN and INCEPTA implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).
Boston Scientific receives US Food and Drug Administration (FDA) approval and is launching the company's INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers (CRT-P).
Boston Scientific completes enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.
Boston Scientific is launching the company's Z Flex-270 Steerable Sheath in the USA which is a device that is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.
Boston Scientific receives CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers (CRT-P).
Boston Scientific is launching the company's BackStop Gel, a new technology designed to prevent stone migration during procedures used to break up and retrieve urinary stones.
Boston Scientific announces the first published technology assessment in support of the safety, efficacy and long-term positive health outcomes of bronchial thermoplasty (BT) as delivered by the Alair Bronchial Thermoplasty System, a catheter-based device designed to treat patients 18 years or older with severe persistent asthma.
Boston Scientific reveals results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM randomized clinical trials, comprising more than 2,400 patients across three distinct coronary stent platforms: the Platinum Chromium Element platform (ION Paclitaxel-Eluting Stent System (TAXUS Element) and PROMUS Element Everolimus-Eluting Stent System), the Xience V/PROMUS Everolimus-Eluting Stent System, and the TAXUS Express Paclitaxel-Eluting Stent System.
Boston Scientific and Lumenis, the market leader in holmium laser technology, sign a five-year contract extending the existing commercial agreement between the two companies and promoting continued investments in laser and fibre product development for urologic applications.
Boston Scientific is reporting the first implants of a TELIGEN implantable cardioverter defibrillator (ICD) in China which were performed by Farong Shen, MD, in Zhejiang Hospital, Hangzhou and Wei Hua, MD, in Fuwai Hospital, Beijing, China.
Boston Scientific is welcoming positive results from three studies of the WallFlex Enteral Stent Systems, a family of self-expanding metal stents (SEMS) used to alleviate obstructive symptoms caused by cancers of the gastrointestinal tract.
Boston Scientific is launching the TruePath CTO Device, designed to facilitate the crossing of chronic total occlusions (CTOs, or complete blockages) within the peripheral vasculature, to the US market.
Boston Scientific is launching the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound (EUS) guidance for cancer diagnosis in organs adjacent to the gastrointestinal tract.
Boston Scientific receives CE Mark approval of the Infinion 16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
Boston Scientific is reporting nine-month clinical endpoint data from its ORION trial, demonstrating excellent outcomes for the company's Epic Self-Expanding Nitinol Stent System in patients with iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow.
Boston Scientific is launching in the USA the company's Charger PTA Balloon Catheter, a 0.035 inch percutaneous transluminal angioplasty (PTA) balloon catheter designed for a wide range of peripheral angioplasty procedures.
Boston Scientific receives US Food and Drug Administration (FDA) approval of the Infinion 16 Percutaneous Lead for its Precision Plus Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
